Revaxis


Manufacturer: Sanofi Pasteur MSD Generic name: Diphtheria, tetanus and poliomyelitis (inactivated) vaccine (adsorbed, reduced antigen(s) content) Revaxis Safety Information publicly available for Revaxis is limited. The manufacturer states that the adverse reactions listed further below were found in clinical trials but gives no further detail. None of the regulators have published any further information. I’m therefore not in a position to evaluate the studies at this time. Revaxis Efficacy Sanofi Pasteur says that the vaccine produced good antibody responses in clinical trials and that these were still evident after 2 years follow-up. There is no mention of a proper efficacy trial but as usual, immunogenicity is assumed to be the same as immunity. Due to the limited information published for Revaxis, I cannot evaluate its efficacy further at this time. Contraindications according to the manufacturer Do not use Revaxis if you or your child: is allergic (hypersensitive) to the active substances of Revaxis any of the other ingredients neomycin, streptomycin or polymyxin B which can be present
in trace amounts has ever had an allergic reaction to any vaccine for diphtheria, tetanus or
polio has ever had any neurological problems (such as weakness or numbness)
after a previous injection of a vaccine against diphtheria or tetanus. has an acute severe illness (infection) with a high temperature. The vaccination will be delayed until you/your child has recovered. A minor infection is not usually a reason to postpone vaccination. Your doctor or nurse will decide if you or your child should receive the vaccine. Take special care with Revaxis
Tell your doctor or nurse before vaccination if you or your child: has a blood disorder where you or your child bruise or bleed easily (such as haemophilia or thrombocytopenia). has ever had a temporary loss of movement and feeling in all or part of the body…

This content is for VIP members only.
Log In Register